Using a quantitative immunoautoradiographic technique with simultaneously exposed internal standards, antigenic sites on A1, A1B, A2 and A2B erythrocytes were quantitated. The binding of purified radioiodinated rabbit anti-A antibodies was studied by the direct incubation technique. 61 normal individuals and 44 patients suffering from leukaemia and other haematological disorders such as polycythaemia vera (PV) and aplastic anaemia (Ap1.A) were investigated. Among the normal volunteers, antigenic sites gradually increased up to 3 months of life, later on they were comparable with the values of adults. A reduction of more than 50% in the antigenic sites was observed in all cases of Apl.A. 50–70% of patients with various forms of leukaemia had a decrease in antigenicity. 1 patient suffering from acute unclassified leukaemia showed two populations of red cells. This case differed from natural O/A1 chimerism where A1 erythrocytes had normal antigenicity while in the patient, A1 antigens were depressed. 2 patients (1 with acute lymphoblastic leukaemia, 1 with Apl.A) who were investigated after allogenic bone marrow transplantation had a marked decrease in antigenic sites. Reasons for A antigenic variations in haematological disorders are discussed.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.